4Basebio (4BB.L) Stock Price

4Basebio Price

LSE·CLOSED
5.63
​
Market closed

Revenue has compounded at 43.3% per year over the past 6 years to 806,000.00 GBP. 4Basebio's net margin stands at -2,097.4%, down from -1,437.8% several years earlier. Analysts set a median price target of 1,734.00 GBP, implying 30,726.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

4Basebio stock price

Access this data via the Eulerpool API

4Basebio business model & stock analysis

4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The company is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. The company is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. The company has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. The company is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.

Frequently asked questions about 4Basebio

Analysts currently set an average price target of 1,734.00 GBP for the 4Basebio stock (median: 1,734.00 GBP), implying +208.3 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the 4Basebio stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect 4Basebio to generate revenue of 1.05 M GBP and earnings per share of -1.14 GBP.

Converted at the current exchange rate, the 4Basebio share trades at 6.64 EUR (5.63 GBP).

The 4Basebio share (4BB.L) is listed on 6 stock exchanges, including: London (4BB.L), XETRA (88Q.DE), Frankfurt (88Q.F), München (88Q.MU), Düsseldorf (88Q.DU).

The expected revenue of 4Basebio is 1.05 M GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of 4Basebio is -17.72 M GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of 4Basebio is currently -4.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the 4Basebio stock.

The price-to-sales ratio (P/S) of 4Basebio is currently 83.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the 4Basebio stock.

The Eulerpool Quality Score for 4Basebio is 3/10.

The ISIN of 4Basebio is GB00BMCLYF79. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of 4Basebio is A3CWA4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of 4Basebio is 4BB.L. The ticker symbol is used to trade 4Basebio shares on the stock exchange.

Fair ValueTerminal
5.74 GBP
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website 4basebio.com
Currency
GBP
Initial public offering
Feb 17, 2021
ISIN
GB00BMCLYF79
Cusip
G3656R104
Market capitalization
87.41 M GBPMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-4.93
P/Ee 2027
-7.03
P/Ee 2028
-11.25
P/Ee 2029
-56.25
P/Ee 2030
14.06
P/Se
83.24
EV/EBIT
—
P/B Ratio
8.65
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-63.51 %
Last updated Oct 11, 2026, 1:48 AM

4Basebio Peer Group

4Basebio Ticker

DÜSSELDORF · 88Q.DUFRANKFURT · 88Q.FLONDON · 4BB.LLONDON STOCK EXCHANGE · 4BB.LMUNICH · 88Q.MUXETRA · 88Q.DE

4Basebio FIGI

88Q:GR · BBG00YGKNWX14BB:LN · BBG00Z46T82388Q:GF · BBG00Z5HKCB888Q:GD · BBG00Z5HKCC788Q:GY · BBG00Z5HKCD688Q:GS · BBG00Z5HKCF488Q:GM · BBG00Z5HKCG388Q:GB · BBG00Z5HKCH24BBGBX:XH · BBG00Z93P0F24BBGBX:XF · BBG00Z93P0H04BBGBX:XE · BBG00Z93P0K64BBGBX:XL · BBG00Z93P0M4

All fundamentals and in-depth analysis of 4Basebio

Our stock analysis for 4Basebio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 4Basebio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.